Trial reportCancer medicine2025
Multi-Institutional Phase II Study on the Efficacy and Safety of Dynamic Tumor-Tracking, Moderately Hypofractionated Intensity-Modulated Radiotherapy in Patients With Locally Advanced Pancreatic Cancer.
Trial report in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Intra-respiratory variation in tumour-diaphragm geometric association as a potential surrogate for dynamic tumour-tracking radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Dynamic tumor tracking for locally advanced pancreatic cancer: precision in motion.Translational cancer research · 2026Article
- Commissioning of an expanded-field radiation technique using a gimbal-mounted linear accelerator.Physics and imaging in radiation oncology · 2026Article
- Effect of First-Line Chemotherapy Alone Versus First-Line Chemotherapy Plus Radiotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer in the IMRT Era: A Retrospective Cohort Study.Cancer reports (Hoboken, N.J.) · 2026Article
- First clinical implementation of dynamic tumor-tracking volumetric modulated arc therapy with a gimbal-mounted linac: short delivery time and high precision.Journal of radiation research · 2026Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
backgroundFor delivering high radiation doses to pancreatic tumors, organ motion management is indispensable; however, studies on this are limited. We aimed to evaluate the efficacy and safety of dynamic tumor tracking (DTT) moderately hypofractionated intensity-modulated radiotherapy (IMRT) in patients with locally advanced pancreatic cancer (LAPC).
methodsPatients with histological confirmation for LAPC were included. A linac system, which was mounted with a gimbal function, was used for DTT-IMRT. The prescribed dose was 48 Gy in 15 fractions. The primary endpoint was the 1-year rate of freedom from locoregional progression (FFLP).
resultsDTT-IMRT was successfully administered in 25 patients enrolled from four institutions. The median range of respiratory motion during DTT-IMRT was 9.8 mm (range: 3.5-27.3 mm), and the median tracking accuracy was 2.6 mm (range: 0.7-5.2 mm). With a median follow-up period of 13.9 months, the 1-year FFLP rate was 75.3% (lower limit of one-sided 80% confidence interval [CI]: 60.2%), which satisfied the predetermined primary endpoint. One-year locoregional progression-free survival, progression-free survival, and overall survival were 56.0% (95% CI: 34.8%-72.7%), 44.0% (95% CI: 24.5%-61.9%), and 60.0% (95% CI: 38.4%-76.1%), respectively. Regarding nonhematologic toxicities, grade 3 acute gastrointestinal (GI) toxicity was observed in two patients (8%), and two patients (8%) each experienced grade 3 late GI and non-GI toxicities. No grade 4 or 5 nonhematologic toxicities were observed.
conclusionsDTT moderately hypofractionated IMRT shows preferable locoregional control without significant toxicity in patients with LAPC.
trial registrationUMIN000017521.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.